Symbols

KYMR

Kymera Therapeutics·NASDAQ

--(--)

KYMR fundamentals

KYMR Q4 2025 Earnings

Kymera Therapeutics (KYMR) released its earnings on Feb 26, 2026: revenue was 2.87M (YoY -61.17%), missed estimates; EPS was -0.97 (YoY -10.23%), missed estimates.

Revenue / YoY

2.87M

-61.17%

EPS / YoY

-0.97

-10.23%

Report date

Feb 26, 2026

KYMR Earnings Call Summary for Q4,2025

Breakthrough STAT6 Program: Phase IIb AD trial enrollment on track for mid-2027 data; asthma trial dosing begins Q1 2026.
$1.6B Cash Runway: Supports Phase IIb trials and pipeline expansion into 2029.
IRF5 First-in-Human Study: Initiated with target of 90% IRF5 knockdown, positioning for lupus proof-of-concept.
Strategic Collaborations: $750M potential from Gilead CDK2 program and $1B from Sanofi IRAK4 program.

Earnings

EPS

Revenue

Revenue & Expenses

KYMR has released its 2025 Q4 earnings report, with revenue of 2.87M, reflecting a YoY change of -61.18%, and net profit of -86.98M, showing a YoY change of -22.94%. The Sankey diagram below clearly presents KYMR's revenue sources and cost distribution.

Key Indicators

Kymera Therapeutics (KYMR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Kymera Therapeutics (KYMR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Kymera Therapeutics (KYMR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Kymera Therapeutics (KYMR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown